HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive

Science Signaling

Volumn 8, Issue 378, 2015, Pages

  Singh, Navneet ^a   Joshi, Rashika ^a   Komurov, Kakajan ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA UROGASTRONE; HUMAN EPIDERMAL GROWTH FACTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN IRE1; PROTEIN IRE1ALPHA; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; ERN1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MTOR PROTEIN, HUMAN; PROTEIN SERINE THREONINE KINASE; RIBONUCLEASE; TARGET OF RAPAMYCIN KINASE;

AMPLICON; ANIMAL CELL; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CELL DEATH; CHROMOSOME 17; CONTROLLED STUDY; COPY NUMBER VARIATION; ENDOPLASMIC RETICULUM ASSOCIATED DEGRADATION; ENDOPLASMIC RETICULUM STRESS; ESSENTIAL GENE; GENE CONTROL; GENE DOSAGE; GENE LOCUS; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; NONHUMAN; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; UPREGULATION; BREAST TUMOR; ENDOPLASMIC RETICULUM; FEMALE; GENETICS; METABOLISM; PATHOLOGY; PROTEIN DEGRADATION; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; ENDORIBONUCLEASES; FEMALE; HUMANS; MAP KINASE KINASE 4; MAP KINASE SIGNALING SYSTEM; PROTEIN-SERINE-THREONINE KINASES; PROTEOLYSIS; RECEPTOR, ERBB-2; TOR SERINE-THREONINE KINASES;

EID: 84929904162     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.aaa6922     Document Type: Article

References (57)

1. The Cancer Genome Atlas, S. V. Sharma, J. Settleman, Oncogene addiction: Setting the stage for molecularly targeted cancer therapy. Genes Dev. 21, 3214-3231 (2007).
2. P. Workman, P. A. Clarke, Resisting targeted therapy: Fifty ways to leave your EGFR. Cancer Cell 19, 437-440 (2011).
3. H. M. Stern, Improving treatment of HER2-positive cancers: Opportunities and challenges. Sci. Transl. Med. 4, 127rv2 (2012).
4. F. McCormick, Cancer therapy based on oncogene addiction. J. Surg. Oncol. 103, 464-467 (2011).
5. J. Luo, N. L. Solimini, S. J. Elledge, Principles of cancer therapy: Oncogene and nononcogene addiction. Cell 136, 823-837 (2009).
6. N. L. Solimini, J. Luo, S. J. Elledge, Non-oncogene addiction and the stress phenotype of cancer cells. Cell 130, 986-988 (2007).
7. T. De Raedt, Z.Walton, J. L. Yecies, D. Li, Y. Chen, C. F. Malone, O. Maertens, S. M. Jeong, R. T. Bronson, V. Lebleu, R. Kalluri, E. Normant, M. C. Haigis, B. D. Manning, K. K. Wong, K. F. Macleod, K. Cichowski, Exploiting cancer cell vulnerabilities to develop a combination therapy for Ras-driven tumors. Cancer Cell 20, 400-413 (2011).
8. M. S. Kumar, D. C. Hancock, M. Molina-Arcas, M. Steckel, P. East, M. Diefenbacher, E. Armenteros-Monterroso, F. Lassailly, N. Matthews, E. Nye, G. Stamp, A. Behrens, J. Downward, The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642-655 (2012).
9. J. Rosenbluh, D. Nijhawan, A. G. Cox, X. Li, J. T. Neal, E. J. Schafer, T. I. Zack, X. Wang, A. Tsherniak, A. C. Schinzel, D. D. Shao, S. E. Schumacher, B. A. Weir, F. Vazquez, G. S. Cowley, D. E. Root, J. P. Mesirov, R. Beroukhim, C. J. Kuo, W. Goessling,W. C. Hahn, b-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 151, 1457-1473 (2012).
10. J. Barretina, G. Caponigro, N. Stransky, K. Venkatesan, A. A. Margolin, S. Kim, C. J. Wilson, J. Lehar, G. V. Kryukov, D. Sonkin, A. Reddy, M. Liu, L. Murray, M. F. Berger, J. E. Monahan, P. Morais, J. Meltzer, A. Korejwa, J. Jane-Valbuena, F. A. Mapa, J. Thibault, E. Bric-Furlong, P. Raman, A. Shipway, I. H. Engels, J. Cheng, G. K. Yu, J. Yu, P. Aspesi Jr., M. de Silva, K. Jagtap, M. D. Jones, L. Wang, C. Hatton, E. Palescandolo, S. Gupta, S. Mahan, C. Sougnez, R. C. Onofrio, T. Liefeld, L. MacConaill, W. Winckler, M. Reich, N. Li, J. P. Mesirov, S.B. Gabriel, G.Getz, K.Ardlie, V. Chan, V. E. Myer, B. L.Weber, J. Porter, M. Warmuth, P. Finan, J. L. Harris,M. Meyerson, T. R. Golub, M. P. Morrissey, W. R. Sellers, R. Schlegel, L. A. Garraway, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603-607 (2012).
11. M. J. Garnett, E. J. Edelman, S. J. Heidorn, C. D. Greenman, A. Dastur, K. W. Lau, P. Greninger, I. R. Thompson, X. Luo, J. Soares, Q. Liu, F. Iorio, D. Surdez, L. Chen, R. J. Milano, G. R. Bignell, A. T. Tam, H. Davies, J. A. Stevenson, S. Barthorpe, S. R. Lutz, F. Kogera, K. Lawrence, A. McLaren-Douglas, X. Mitropoulos, T. Mironenko, H. Thi, L. Richardson, W. Zhou, F. Jewitt, T. Zhang, P. O'Brien, J. L. Boisvert, S. Price, W. Hur, W. Yang, X. Deng, A. Butler, H. G. Choi, J. W. Chang, J. Baselga, I. Stamenkovic, J. A. Engelman, S. V. Sharma, O. Delattre, J. Saez-Rodriguez, N. S. Gray, J. Settleman, P. A. Futreal, D. A. Haber, M. R. Stratton, S. Ramaswamy, U. McDermott, C. H. Benes, Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483, 570-575 (2012).
12. H. W. Cheung, G. S. Cowley, B. A. Weir, J. S. Boehm, S. Rusin, J. A. Scott, A. East, L. D. Ali, P. H. Lizotte, T. C. Wong, G. Jiang, J. Hsiao, C. H. Mermel, G. Getz, J. Barretina, S. Gopal, P. Tamayo, J. Gould, A. Tsherniak, N. Stransky, B. Luo, Y. Ren, R. Drapkin, S. N. Bhatia, J. P. Mesirov, L. A. Garraway, M. Meyerson, E. S. Lander, D. E. Root, W. C. Hahn, Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 108, 12372-12377 (2011).
13. B. Haibe-Kains, N. El-Hachem, N. J. Birkbak, A. C. Jin, A. H. Beck, H. J. Aerts, J. Quackenbush, Inconsistency in large pharmacogenomic studies. Nature 504, 389-393 (2013).
14. D. Hanahan, R. A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646-674 (2011).
15. A. Lane, A. Segura-Cabrera, K. Komurov, A comparative survey of functional footprints of EGFR pathway mutations in human cancers. Oncogene 33, 5078-5089 (2014).
16. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
17. C. Curtis, S. P. Shah, S. F. Chin, G. Turashvili, O. M. Rueda, M. J. Dunning, D. Speed, A.G. Lynch, S. Samarajiwa, Y. Yuan, S. Graf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. McKinney, A. Langerod, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A. L. Borresen-Dale, J. D. Brenton, S. Tavare, C. Caldas, S. Aparicio, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
18. J. Bartkova, Z. Horejsi, K. Koed, A. Kramer, F. Tort, K. Zieger, P. Guldberg, M. Sehested, J. M. Nesland, C. Lukas, T. Orntoft, J. Lukas, J. Bartek, DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434, 864-870 (2005).
19. J. Bartkova, N. Rezaei, M. Liontos, P. Karakaidos, D. Kletsas, N. Issaeva, L. V. Vassiliou, E. Kolettas, K. Niforou, V. C. Zoumpourlis, M. Takaoka, H. Nakagawa, F. Tort, K. Fugger, F. Johansson, M. Sehested, C. L. Andersen, L. Dyrskjot, T. Orntoft, J. Lukas, C. Kittas, T. Helleday, T. D. Halazonetis, J. Bartek, V. G. Gorgoulis, Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444, 633-637 (2006).
20. M. Braig, S. Lee, C. Loddenkemper, C. Rudolph, A. H. Peters, B. Schlegelberger, H. Stein, B. Dorken, T. Jenuwein, C. A. Schmitt, Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436, 660-665 (2005).
21. M. Serrano, A. W. Lin, M. E. McCurrach, D. Beach, S.W. Lowe, Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88, 593-602 (1997).
22. C. J. Sarkisian, B. A. Keister, D. B. Stairs, R. B. Boxer, S. E. Moody, L. A. Chodosh, Dosedependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat. Cell Biol. 9, 493-505 (2007).
23. N. Aceto, S. Duss, G. Macdonald, D. S. Meyer, T. C. Roloff, N. E. Hynes, M. Bentires-Alj, Co-expression of HER2 and HER3 receptor tyrosine kinases enhances invasion of breast cells via stimulation of interleukin-8 autocrine secretion. Breast Cancer Res. 14, R131 (2012).
24. K. Komurov, S. Dursun, S. Erdin, P. T. Ram, NetWalker: A contextual network analysis tool for functional genomics. BMC Genomics 13, 282 (2012).
25. K. Komurov, M. A. White, P. T. Ram, Use of data-biased random walks on graphs for the retrieval of context-specific networks from genomic data. PLOS Comput. Biol. 6, e1000889 (2010).
26. C. Hetz, The unfolded protein response: Controlling cell fate decisions under ER stress and beyond. Nat. Rev. Mol. Cell Biol. 13, 89-102 (2012).
27. J. L. Brodsky, Cleaning up: ER-associated degradation to the rescue. Cell 151, 1163-1167 (2012).
28. J. C. Christianson, J. A. Olzmann, T. A. Shaler, M. E. Sowa, E. J. Bennett, C. M. Richter, R. E. Tyler, E. J. Greenblatt, J. W. Harper, R. R. Kopito, Defining human ERAD networks through an integrative mapping strategy. Nat. Cell Biol. 14, 93-105 (2012).
29. P. Magnaghi, R. D'Alessio, B. Valsasina, N. Avanzi, S. Rizzi, D. Asa, F. Gasparri, L. Cozzi, U. Cucchi, C. Orrenius, P. Polucci, D. Ballinari, C. Perrera, A. Leone, G. Cervi, E. Casale, Y. Xiao, C. Wong, D. J. Anderson, A. Galvani, D. Donati, T. O'Brien, P. K. Jackson, A. Isacchi, Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat. Chem. Biol. 9, 548-556 (2013).
30. T. F. Chou, S. J. Brown, D. Minond, B. E. Nordin,K. Li, A. C. Jones, P. Chase,P. R. Porubsky, B. M. Stoltz, F. J. Schoenen, M. P. Patricelli, P. Hodder, H. Rosen, R. J. Deshaies, Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Proc. Natl. Acad. Sci. U.S.A. 108, 4834-4839 (2011).
31. Q. Wang, L. Li, Y. Ye, Inhibition of p97-dependent protein degradation by Eeyarestatin I. J. Biol. Chem. 283, 7445-7454 (2008).
32. T. F. Chou, R. J. Deshaies, Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J. Biol. Chem. 286, 16546-16554 (2011).
33. Q.Wang, B.A. Shinkre, J. G.Lee, M.A.Weniger,Y. Liu,W. Chen, A.Wiestner,W. C. Trenkle, Y. Ye, The ERAD inhibitor Eeyarestatin I is a bifunctional compound with a membranebinding domain and a p97/VCP inhibitory group. PLOS One 5, e15479 (2010).
34. J. C. Chen, M. L. Wu, K. C. Huang, W. W. Lin, HMG-CoA reductase inhibitors activate the unfolded protein response and induce cytoprotective GRP78 expression. Cardiovasc. Res. 80, 138-150 (2008).
35. R. M. Fox, C. D. Hanlon, D. J. Andrew, The CrebA/Creb3-like transcription factors are major and direct regulators of secretory capacity. J. Cell Biol. 191, 479-492 (2010).
36. G. Liang, T. E. Audas, Y. Li, G. P. Cockram, J. D. Dean, A. C. Martyn, K. Kokame, R. Lu, Luman/CREB3 induces transcription of the endoplasmic reticulum (ER) stress response protein Herp through an ER stress response element. Mol. Cell. Biol. 26, 7999-8010 (2006).
37. R. M. Young, D. Ackerman, Z. L. Quinn, A. Mancuso, M. Gruber, L. Liu, D. N. Giannoukos, E. Bobrovnikova-Marjon, J. A. Diehl, B. Keith, M. C. Simon, Dysregulated mTORC1 renders cells critically dependent on desaturated lipids for survival under tumor-like stress. Genes Dev. 27, 1115-1131 (2013).
38. T. W. Miller, J. T. Forbes, C. Shah, S. K. Wyatt, H. C. Manning, M. G. Olivares, V. Sanchez, T. C. Dugger, N. de Matos Granja, A. Narasanna, R. S. Cook, J. P. Kennedy, C.W. Lindsley, C. L. Arteaga, Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin. Cancer Res. 15, 7266-7276 (2009).
39. J. H. Bullard, E. Purdom, K. D. Hansen, S. Dudoit, Evaluation of statistical methods for normalization and differential expression in mRNA-Seq experiments. BMC Bioinformatics 11, 94 (2010).
40. R. Sano, J. C. Reed, ER stress-induced cell death mechanisms. Biochim. Biophys. Acta 1833, 3460-3470 (2013).
41. C. Ndong, R. P. Landry, M. Saha, E. A. Romero-Sandoval, Mitogen-activated protein kinase (MAPK) phosphatase-3 (MKP-3) displays a p-JNK-MAPK substrate preference in astrocytes in vitro. Neurosci. Lett. 575, 13-18 (2014).
42. O. Bermudez, G. Pages, C. Gimond, The dual-specificity MAP kinase phosphatases: Critical roles in development and cancer. Am. J. Physiol. Cell Physiol. 299, C189-C202 (2010).
43. G. Molina, A. Vogt, A. Bakan, W. Dai, P. Queiroz de Oliveira, W. Znosko, T. E. Smithgall, I. Bahar, J. S. Lazo, B. W. Day, M. Tsang, Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nat. Chem. Biol. 5, 680-687 (2009).
44. S. Giuriato, D. W. Felsher, How cancers escape their oncogene habit. Cell Cycle 2, 329-332 (2003).
45. C. Yewale, D. Baradia, I. Vhora, S. Patil, A. Misra, Epidermal growth factor receptor targeting in cancer: A review of trends and strategies. Biomaterials 34, 8690-8707 (2013).
46. L. Jerby-Arnon, N. Pfetzer, Y. Y. Waldman, L. McGarry, D. James, E. Shanks, B. Seashore-Ludlow, A. Weinstock, T. Geiger, P. A. Clemons, E. Gottlieb, E. Ruppin, Predicting cancer-specific vulnerability via data-driven detection of synthetic lethality. Cell 158, 1199-1209 (2014).
47. F. L. Muller, S. Colla, E. Aquilanti, V. E. Manzo, G. Genovese, J. Lee, D. Eisenson, R. Narurkar, P. Deng, L. Nezi,M. A. Lee, B. Hu, J. Hu, E. Sahin, D. Ong, E. Fletcher-Sananikone, D. Ho, L. Kwong, C. Brennan, Y. A. Wang, L. Chin, R. A. DePinho, Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488, 337-342 (2012).
48. D. Nijhawan, T. I. Zack, Y. Ren, M. R. Strickland, R. Lamothe, S. E. Schumacher, A. Tsherniak, H. C. Besche, J. Rosenbluh, S. Shehata, G. S. Cowley, B. A. Weir, A. L. Goldberg, J. P. Mesirov, D. E. Root, S. N. Bhatia, R. Beroukhim, W. C. Hahn, Cancer vulnerabilities unveiled by genomic loss. Cell 150, 842-854 (2012).
49. Y. Chien, S. Kim, R. Bumeister, Y. M. Loo, S. W. Kwon, C. L. Johnson, M. G. Balakireva, Y. Romeo, L. Kopelovich, M. Gale Jr., C. Yeaman, J. H. Camonis, Y. Zhao, M. A. White, RalB GTPase-mediated activation of the IkB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 127, 157-170 (2006).
50. A. Singh, M. F. Sweeney,M. Yu, A. Burger, P. Greninger, C. Benes, D. A. Haber, J. Settleman, TAK1 inhibition promotes apoptosis in KRAS-dependent colon cancers. Cell 148, 639-650 (2012).
51. C. Denoyelle, G. Abou-Rjaily, V. Bezrookove, M. Verhaegen, T. M. Johnson, D. R. Fullen, J. N. Pointer, S. B. Gruber, L. D. Su, M. A. Nikiforov, R. J. Kaufman, B. C. Bastian, M. S. Soengas, Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat. Cell Biol. 8, 1053-1063 (2006).
52. B. Luo, A. S. Lee, The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies. Oncogene 32, 805-818 (2013).
53. Y. Ma, L. M. Hendershot, The role of the unfolded protein response in tumour development: Friend or foe? Nat. Rev. Cancer 4, 966-977 (2004).
54. C. Hetz, E. Chevet, H. P. Harding, Targeting the unfolded protein response in disease. Nat. Rev. Drug Discov. 12, 703-719 (2013).
55. Y. C. Chae, M. C. Caino, S. Lisanti, J. C. Ghosh, T. Dohi, N. N. Danial, J. Villanueva, S. Ferrero, V. Vaira, L. Santambrogio, S. Bosari, L. R. Languino, M. Herlyn, D. C. Altieri, Control of tumor bioenergetics and survival stress signaling by mitochondrial HSP90s. Cancer Cell 22, 331-344 (2012).
56. L. S. Hart, J. T. Cunningham, T. Datta, S. Dey, F. Tameire, S. L. Lehman, B. Qiu, H. Zhang, G. Cerniglia, M. Bi, Y. Li, Y. Gao, H. Liu, C. Li, A. Maity, A. Thomas-Tikhonenko, A. E. Perl, A. Koong, S. Y. Fuchs, J. A. Diehl, I. G. Mills, D. Ruggero, C. Koumenis, ER stressmediated autophagy promotes Myc-dependent transformation and tumor growth. J. Clin. Invest. 122, 4621-4634 (2012).
57. K. Komurov, J. T. Tseng, M. Muller, E. G. Seviour, T. J. Moss, L. Yang, D. Nagrath, P. T. Ram, The glucose-deprivation network counteracts lapatinib-induced toxicity in resistant ErbB2-positive breast cancer cells. Mol. Syst. Biol. 8, 596 (2012).